Browsing by Author "Calligaris, Sebastián"
Now showing 1 - 6 of 6
Results Per Page
Sort Options
Item A REDCap application that links researchers, animal facility staff and members of the IACUC in animal health monitoring(Sage Journals, 2019) Carvajal, Cristobal; Vallejos, Catalina; Lemaitre, Dominique; Ruiz, Jorge; Guzmán, Camila; Aguilera, Valentina; Baño, Diego; Calligaris, SebastiánLos estudios de investigación que requieren la experimentación con animales son regulados por el Comité Institucional para el Cuidado y Uso de Animales de Laboratorio (CICUAL). Con este fin, el CICUAL debe integrar la información suministrada por los investigadores de cada estudio preclínico y por los veterinarios de Bioterio para poder controlar y aprobar el proceso. Utilizar un sistema en papel para recoger datos del bienestar y la salud de los animales es una práctica común pero que requiere mucho tiempo, propensa a errores de lectura y transcripción, sin nombrar todos los inconvenientes que tiene para veterinarios e investigadores que desean tomar decisiones colaborativas y precisas cuando el bienestar del animal está en peligro. Hemos creado un Sistema Web para gestión de bases de datos que se centra en la salud animal con el potencial de mejorar su bienestar. El sistema de gestión de datos utiliza el software REDCap, que permite la integración de datos para ofrecer una solución para la evaluación del bienestar animal. El programa propuesto incluye indicadores claves del estado de salud general, como el entorno, información física/nutricional y parámetros de comportamiento durante la cría y la experimentación con animales, como componentes importantes del bienestar animal. Asimismo, el sistema facilita la comunicación de esta información entre los investigadores, el personal de Bioterio y el CICUAL. REDCap está disponible para organizaciones sin fines de lucro de lucro y adáptandose a los requerimientos propios de las instituciones interesadas y responsables del cuidado de animales utilizados en los estudios de investigación. REDCap es una herramienta excelente para fomentar buenas prácticas que beneficien la salud de los animales de experimentación.Item Circulating miR-19b and miR181b are potential biomarkers for diabetic cardiomyopathy(Nature Publishing Group, 2017) Uribe, Camila; León, Luis; Fernández, Mauricio; Contador, David; Calligaris, SebastiánDiabetic cardiomyopathy is characterized by metabolic changes in the myocardium that promote a slow and silent dysfunction of muscle fibers, leading to myocardium remodelling and heart failure, independently of the presence of coronary artery diseases or hypertension. At present, no imaging methods allow an early diagnosis of this disease. Circulating miRNAs in plasma have been proposed as biomarkers in the prognosis of several cardiac diseases. This study aimed to determine whether circulating miRNAs could be potential biomarkers of diabetic cardiomyopathy. Mice that were fed with a high fat diet for 16 months, showed metabolic syndrome manifestations, cardiac hypertrophy (without hypertension) and a progressive cardiac function decline. At 16 months, when maximal degree of cardiac dysfunction was observed, 15 miRNAs from a miRNA microarray screening in myocardium were selected. Then, selected miRNAs expression in myocardium (at 4 and 16 months) and plasma (at 4, 12 and 16 months) were measured by RT-qPCR. Circulating miR-19b-3p and miR-181b-5p levels were associated with myocardium levels during the development of diabetic cardiomyopathy (in terms of cardiac dysfunction), suggesting that these miRNAs could be suitable biomarkers of this disease in asymptomatic diabetic patients.Item Intravenous administration of bone marrow-derived multipotent mesenchymal stromal cells has a neutral effect on obesity-induced diabetic cardiomyopathy(Sociedad de Biología de Chile, 2013) Calligaris, Sebastián; Conget, PauletteObesity is a major global health issue. Obese patients develop metabolic syndrome, which is a cluster of clinical features characterized by insulin resistance and dyslipidemia. Its cardiac manifestation, diabetic cardiomyopathy, leads to heart failure. Bone marrow-derived multipotent mesenchymal stromal cells, also referred to as mesenchymal stem cells (MSC) are envisioned as a therapeutic tool not only for cardiovascular diseases but also for other degenerative conditions. Our aim was to evaluate whether the intravenous administration of MSC modifies cardiac dysfunction in obese mice. To this end, C57BL/6 mice were fed a regular (normal) or high-fat diet (obese). Obese animals received the vehicle (obese), a single dose (obese + 1x MSC) or three doses (obese + 3x MSC) of 0.5x106 syngeneic MSC. Two to three months following MSC administration, cardiac function was assessed by cardiac catheterization, at basal condition and after a pharmacological stress. Compared to normal mice, obese mice presented hyperglycemia, hyperinsulinemia, hypercholesterolemia and cardiac dysfunction after stress condition. Exogenous MSC neither improved nor impaired this cardiac dysfunction. Thus, intravenous administration of MSC has neutral effect on obesity-induced diabetic cardiomyopathyItem Mesenchymal stem cell therapy for doxorubicin cardiomyopathy: hopes and fears(Biomed Central Ltd., 2015) Ezquer, Fernando; Gutiérrez, Jaime; Ezquer, Marcelo; Caglevic, Christian; Salgado, Helio; Calligaris, SebastiánChemotherapy has made an essential contribution to cancer treatment in recent decades despite its adverse effects. As cancer survivors have increased, concern about ex-patient lifespan has become more important too. Doxorubicin is an effective anti-neoplastic drug that produces a cardiotoxic effect. Cancer survivors who received doxorubicin became more vulnerable to cardiac disease than the normal population did. Many efforts have been made to prevent cardiac toxicity in patients with cancer. However, current therapies cannot guarantee permanent cardiac protection. One of their main limitations is that they do not promote myocardium regeneration. In this review, we summarize and discuss the promising use of mesenchymal stem cells for cardio-protection or cardio-regeneration therapies and consider their regenerative potential without leaving aside their controversial effects on tumor progression.Item Multipotent mesenchymal stromal cells: A promising strategy to manage alcoholic liver disease(WJG Press, 2016) Ezquer, Fernando; Bruna, Flavia; Calligaris, Sebastián; Conget, Paulette; Ezquer, MarceloChronic alcohol consumption is a major cause of liver disease. The term alcoholic liver disease (ALD) refers to a spectrum of mild to severe disorders including steatosis, steatohepatitis, cirrhosis, and hepatocellular carcinoma. With limited therapeutic options, stem cell therapy offers significant potential for these patients. In this article, we review the pathophysiologic features of ALD and the therapeutic mechanisms of multipotent mesenchymal stromal cells, also referred to as mesenchymal stem cells (MSCs), based on their potential to differentiate into hepatocytes, their immunomodulatory properties, their potential to promote residual hepatocyte regeneration, and their capacity to inhibit hepatic stellate cells. The perfect match between ALD pathogenesis and MSC therapeutic mechanisms, together with encouraging, available preclinical data, allow us to support the notion that MSC transplantation is a promising therapeutic strategy to manage ALD onset and progression.Item Subclinical Detection of Diabetic Cardiomyopathy with MicroRNAs: Challenges and Perspectives(Hindawi Publishing Corporation, 2016) León, Luis; Rani, Sweta; Fernández, Mauricio; Larico, Martín; Calligaris, SebastiánThe prevalence of cardiac diabetic diseases has been increased around the world, being the most common cause of death and disability among diabetic patients. In particular, diabetic cardiomyopathy is characterized with a diastolic dysfunction and cardiac remodelling without signs of hypertension and coronary artery diseases. In an early stage, it is an asymptomatic disease; however, clinical studies demonstrate that diabetic myocardia are more vulnerable to injury derived by acute myocardial infarct and are the worst prognosis for rehabilitation. Currently, biochemical and imaging diagnostic methods are unable to detect subclinical manifestation of the disease (prior to diastolic dysfunction). In this review, we elaborately discuss the current scientific evidences to propose circulating microRNAs as promising biomarkers for early detection of diabetic cardiomyopathy and, then, to identify patients at high risk of diabetic cardiomyopathy development. Moreover, here we summarise the research strategies to identify miRNAs as potential biomarkers, present limitations, challenges, and future perspectives.